Barclays Raises its Price Target on Jazz Pharmaceuticals (JAZZ) to $225 [Yahoo! Finance]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
On April 19, 2026, Barclays analyst Etzer Darout raised the price target on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $225 from $224 and maintained an Overweight rating on the shares as part of a Q1 preview across the small and mid-cap biotechnology group. Earlier in April, Raymond James resumed coverage of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) with an Outperform rating and a $227 price target, saying the story has moved beyond the “it looks inexpensive/fairly valued, but where can I get upside?” view, citing improved visibility into the tail value of the Epidiolex franchise and “highly competitive” data from zanidatamab in gastroesophageal adenocarcinoma. Barclays Raises its Price Target on Jazz Pharmaceuticals (JAZZ) to $225 Last month, Piper Sandler raised its price target on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $232 from $219 and maintained an Overweight rating, noting the company trades at about seven times EV/2026E EBITDA while offering visibility into double-digit
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- How ASCO Phase 3 Oncology Data May Reshape Jazz Pharmaceuticals' (JAZZ) Investment Narrative [Yahoo! Finance]Yahoo! Finance
- Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals Scores FDA Priority Review for Ziihera Combinations in First-Line HER2+ Gastroesophageal Cancer [TheStreet.com]TheStreet.com
- Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEAPR Newswire
JAZZ
Earnings
- 2/24/26 - Beat
JAZZ
Sec Filings
- 4/24/26 - Form 10-K/A
- 4/3/26 - Form 4
- 4/1/26 - Form 144
- JAZZ's page on the SEC website